drugset / Trial / NCT07178912
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Phase 2
Not yet recruiting
60 enrolled
M.D. Anderson Cancer Center
Amgen · collabAscentage Pharma Group Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Timeline
- Start
- 2026-08-27
- Primary completion
- 2031-09-30
- Completion
- 2033-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Subject | Olverembatinib | Small molecule | — | Oral |